250 related articles for article (PubMed ID: 33073917)
1. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Ahn D; Lee GJ; Sohn JH; Lee JE
Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
[TBL] [Abstract][Full Text] [Related]
2. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
[TBL] [Abstract][Full Text] [Related]
3. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
[TBL] [Abstract][Full Text] [Related]
4. Primary concurrent chemoradiation therapy with triweekly cisplatin as a standard protocol in patients aged ≥65 years with head and neck squamous cell carcinoma.
Ahn D; Kwak JH; Lee GJ; Sohn JH; Lee JE
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e239-e247. PubMed ID: 36178306
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
8. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
9. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
[TBL] [Abstract][Full Text] [Related]
10. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
11. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
12. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
13. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
16. Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.
Morse RT; Ganju RG; Neeranjun R; Gan GN; Cao Y; Neupane P; Kakarala K; Shnayder Y; Lominska CE
Chemotherapy; 2023; 68(1):35-43. PubMed ID: 35882207
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation.
Rühle A; Weymann M; Behrens M; Marschner S; Haderlein M; Fabian A; Senger C; Dickstein DR; Kraft J; von der Grün J; Chen E; Aquino-Michaels T; Domschikowski J; Bickel A; Altay-Langguth A; Kalinauskaite G; Lewitzki V; Bonomi M; Blakaj DM; Jhawar SR; Baliga S; Barve R; Ferentinos K; Zamboglou C; Schnellhardt S; Haehl E; Spohn SKB; Kuhnt T; Zöller D; Guckenberger M; Budach V; Belka C; Bakst R; Mayer A; Schmidberger H; Grosu AL; Balermpas P; Stromberger C; Nicolay NH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1282-1293. PubMed ID: 37914144
[TBL] [Abstract][Full Text] [Related]
18. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
